MAZE vs PATH
Maze Therapeutics, Inc. Common Stock (MAZE) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported MAZE revenue for 2025-06-30 was $0. Net income was -$66.5M. Revenue was down 100.0% from 2024-09-30 to 2025-06-30. MAZE currently screens at market cap $525.3M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
MAZE currently screens at market cap $525.3M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the MAZE and PATH stock pages for the full models.
Not investment advice.